Bioventus (BVS) CEO adds major RSU and option grants, exercises awards

Rhea-AI Filing Summary

Bioventus Inc. President and CEO Robert E. Claypoole reported equity compensation changes and an option-related share delivery. On March 13, 2026, he exercised 33,500 restricted stock units into 33,500 shares of Class A common stock at $0.00 per share and had 14,553 shares withheld at $8.62 per share to cover tax obligations, leaving 135,944 Class A shares held directly.

On the same date, he received grants of 278,000 restricted stock units and 309,000 stock options for Class A common stock, with the options carrying an exercise price of $8.62 and expiring on March 13, 2036. Footnotes state that the RSUs and options granted in 2025 and 2026 vest in four equal annual installments starting on the first four anniversaries of March 15, 2025 and March 15, 2026, subject to his continued service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Claypoole Robert E

(Last) (First) (Middle)

4721 EMPEROR BOULEVARD, SUITE 100

(Street)

DURHAM NC 27703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bioventus Inc. [ BVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	03/13/2026		M		33,500	A	$0	150,497	D
Class A Common Stock	03/13/2026		F		14,553	D	$8.62	135,944	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/14/2025		A		134,000		(2)	(2)	Class A Common Stock	134,000	$0	134,000	D
Stock Option (Right to Buy)	$9.61	03/14/2025		A		153,000		(2)	03/14/2035	Class A Common Stock	153,000	$0	153,000	D
Restricted Stock Units	(1)	03/13/2026		A		278,000		(3)	(3)	Class A Common Stock	278,000	$0	278,000	D
Stock Option (Right to Buy)	$8.62	03/13/2026		A		309,000		(3)	03/13/2036	Class A Common Stock	309,000	$0	309,000	D
Restricted Stock Units	(1)	03/13/2026		M			33,500	(2)	(2)	Class A Common Stock	33,500	$0	100,500	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.

2. The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 15, 2025, in each case subject to the Reporting Person continuing in service through the applicable vesting date.

3. The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 15, 2026, in each case subject to the Reporting Person continuing in service through the applicable vesting date.

Remarks:

	/s/ Anthony D'Adamio, Attorney-in-Fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Bioventus (BVS) CEO Robert Claypoole report?

Robert Claypoole reported exercising 33,500 restricted stock units into Class A shares and a related tax-withholding share disposition. He also reported large new grants of restricted stock units and stock options tied to Bioventus Class A common stock.

How many Bioventus (BVS) shares does the CEO hold after these transactions?

After the reported transactions, Robert Claypoole holds 135,944 shares of Bioventus Class A common stock directly. This figure comes from the post-transaction ownership line in the filing’s non-derivative table for the final tax-withholding disposition entry.

What equity awards did the Bioventus (BVS) CEO receive on March 13, 2026?

On March 13, 2026, the CEO received 278,000 restricted stock units and stock options for 309,000 shares of Bioventus Class A common stock, with the options carrying an exercise price of $8.62 per share and an expiration date in March 2036.

How do the new Bioventus (BVS) RSU and option grants vest for the CEO?

The filing states that the RSUs and options granted in 2025 and 2026 vest in four equal installments on the first four anniversaries of March 15, 2025 and March 15, 2026, respectively, contingent on Robert Claypoole’s continued service through each vesting date.

Was there any open-market buying or selling by the Bioventus (BVS) CEO?

The reported transactions show derivative exercises, grants, and tax-withholding dispositions, not open-market purchases or sales. Shares withheld at $8.62 per share were used to satisfy tax obligations tied to equity awards rather than discretionary trading in the open market.

What earlier Bioventus (BVS) equity awards to the CEO are referenced?

The data references grants dated March 14, 2025 of 134,000 restricted stock units and 153,000 stock options with a $9.61 exercise price, expiring in March 2035. These awards are described as vesting in four equal annual installments from March 15, 2025, subject to continued service.